Dados B3 › VIVT3 × OIBR3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | VIVT3 | OIBR3 | year |
|---|---|---|---|
| ROE | 8.9% | -243.5% | 2021 |
| ROIC | 6.7% | -91.3%! | 2022 |
| ROA | 4.5% | 41.9%! | 2024 |
| Gross margin | 43.9% | -45.7%! | 2024 |
| EBIT margin | 15.5% | -61.5%! | 2024 |
| Net margin | 10.0% | 302.2%! | 2024 |
| Net debt/EBITDA | 0.55x | 11.73x | 2021 |
| Current ratio | 0.94x | 1.00x! | 2024 |
| Revenue growth (1y) | 7.2% | -25.3%! | 2024 |
| Revenue growth (5y CAGR) | 4.8% | -21.2%! | 2024 |
| Piotroski F-Score | 8/9 | 5/9! | 2024 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | VIVT3 | OIBR3 | year |
|---|---|---|---|
| P/E | 21.78x | 0.00x | 2025 × 2024 |
| P/B | 1.95x | — | 2025 × 2024 |
| EV/EBITDA | 5.95x | — | 2025 × 2024 |
| FCF yield | 8.4% | -352,559.1% | 2025 × 2024 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 13:38 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it